Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“ASH25 ‘decoding DDX41 mutant HR-MDS and AML’
Conclusion:
- Not every DDX41-mutant HR-MDS/AML responds well to venetoclax plus HMA.
- No survival difference between pathogenic vs VUS variants.
- Splicing-factor co-mutations predicted worse outcomes, while allo-HCT trended better.
Highlights need for larger cohorts to refine predictors.”
More updates from ASH25 on OncoDaily.